A Secret Weapon For Nemifitide diTFA
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal demo goals were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis i